The School of Medicine is the medical school of the University of Leeds, in the city of Leeds, West Yorkshire, England. The School of Medicine was founded in 1831.The School of Medicine now forms part of the University's Faculty of Medicine and Health. The School is composed of institutes located at multiple sites in West Yorkshire including the Worsley Building, LIGHT, St James's Campus, and Chapel Allerton Hospital. The School of Medicine is primarily linked with two major hospitals for clinical teaching: the Leeds General Infirmary and St James's University Hospital, both run by the Leeds Teaching Hospitals NHS Trust, alongside smaller district NHS Trusts.
Abstract Sodium fluorescein (SF) is a safe and established adjunct in adult neuro-oncology, aiding intraoperative tumour visualisation. Its role in paediatric practice remains undefined. We evaluated feasibility, safety and impact of FS in a single UK paediatric neurosurgery centre. We conducted a retrospective analysis of surgically treated paediatric tumour cases between January-2020 and September 2025. Demographic, radiological, histological, and clinical outcome data collected and analysed. Cases stratified into SF and Non-SF cohorts. SF administered intravenously 30-45 minutes prior to expected tumour exposure. Intraoperative fluorescence evaluated using 560-nm-integrated-microscope filter. From 110 tumour cases identified. 24 underwent SF-aided surgery (M:F 1.06:1; mean age 8.4y, range 0.36–17.73). For tumour biopsies, 6/24 received SF which confirmed positive fluorescence and all yielded positive pathology (100%). While 17 had biopsy without SF; 2/17 had negative pathology (11.76%). For tumour resection cases, intraoperative fluorescence was concordant with tumour enhancement in 87.5% of cases (21/24); 80.9% WHO Grade 1-2 (13 Pilocytic astrocytoma, 1 SEGA and 3 LGG) and 19.1% WHO Grade 3-4 (1 Medulloblastoma, 2 Glioblastoma, 1 PXA). Fluorescence was absent in 3/24 cases (12.5%), despite enhancement on pre-op MRI (1 DIPG and 2 PXA). There was no significant difference in GTR rates between SF and non-SF groups (12/18 vs 46/69). No SF-related complications were reported. There was no difference in general postoperative complications 1/24 patients in the SF group (4.12%) and 5/86 in the non-SF group (5.81%). In conclusion; SF is a safe and feasible adjunct in paediatric neuro-oncology. There was general concordance between SF fluorescence and post-gadolinium enhancement on MRI. SF appears to be helpful for both tumour resection and biopsy in high and low-grade paediatric tumours. Non-enhancing tumour did not fluoresce. Larger prospective studies will help further define / optimise SF use.